Get Access to Idelalisib in India

Idelalisib is an oral medication approved by the US FDA for the treatment of Haematological malignancies. Chronic Lymphocytic Leukemia and Follicular B-cell Non-Hodgkin Lymphoma are the two types of blood cancers that can be treated with this drug. In CLL, it is given in combination of rituximab, another advanced medication. In case of relapsed follicular B-cell non-Hodgkin lymphoma (FL), Idelalisib is given to the patients who already received two prior therapies. It is also approved in the management of relapsed small lymphocytic lymphoma (SLL). Zydelig is its brand name and it is a product of Gilead Sciences. Idelalisib in India is recommended for patients with no other alternative options. Patients can consider the import option at that time.

Zydelig 100mg and Zydelig 150mg tablets are commercially available. Zydelig in India has a very specific role in geriatric patients who are above 65 years old. Older patients treated for Indolent non-Hodgkin lymphoma and CLL are often prescribed this drug. As a second line option for CLL, the mechanism of action of Idelalisib is noted to be unique. By inhibiting the cell signalling pathways, this drug slows down or stops the growth of cancer cells.

FDA and EMA have given their respective approvals for this drug in 2014. Various leukaemia types can be treated with this drug. The data for the same is being studied. Ongoing clinical research points towards the possibility of expanding its indications as well.